SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-24-018329
Filing Date
2024-05-09
Accepted
2024-05-09 08:00:38
Documents
15
Period of Report
2023-12-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 44356
2 ex10-1.htm EX-10.1 60989
  Complete submission text file 0001493152-24-018329.txt   297317

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE prph-20231228.xsd EX-101.SCH 3027
4 XBRL LABEL FILE prph-20231228_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE prph-20231228_pre.xml EX-101.PRE 22367
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 4378
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-21617 | Film No.: 24928675
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)